Now, one type of weight-loss medication is proving helpful with another health issue. In a study published Feb. 12 in JAMA Psychiatry, researchers report that semaglutide, better known as Ozempic or Wegovy, helped people with alcohol addiction reduce their craving and drink less.

A doctor emphasized that ozempic, a lab-engineered drug, effectively activates GLP-1 receptors for weight loss, unlike foods that offer only temporary effects.

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial of its experimental drug CagriSema — a combination of semaglutide and a medicine called cagrilintide. People on CagriSema lost about 23% of their body weight in a 68-week study, outperforming both drugs when taken alone.

A small study confirms observations what users have observed: the medications reduce their cravings for alcohol.

Anne-Marie Zanzal, 60, and her wife Tonda McKay, 62, have also experienced the more positive changes that weight-loss drugs can have on romantic relationships. They say they had reached the "fat and happy stage of life" but realized being overweight was affecting their energy levels.

GLP-1) receptor agonists, which are used to treat type 2 diabetes and/or obesity, were linked to vision problems in a small study. Here's what doctors have to say.

Millions of Americans use GLP-1 injections like Ozempic to lose weight. A study is questioning whether they can cause vision loss.